Voriconazole in the management of nosocomial invasive fungal infections

Therapeutics and Clinical Risk Management

Volumn 2, Issue 2, 2006, Pages 129-158

  Pemán, Javier ^a   Salavert, Miguel ^a   Cantón, Emilia ^a   Jarque, Isidro ^a   Romá, Eva ^a   Zaragoza, Rafael ^b   Viudes, Ángel ^c   Gobernado, Miguel ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^c PFIZER INC   (United States)

Author keywords

Azole; Moulds; Mycoses; Treatment; Voriconazole; Yeasts

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ASTEMIZOLE; AZITHROMYCIN; CARBAMAZEPINE; CASPOFUNGIN; CYCLODEXTRIN; CYCLOSPORIN; DIGOXIN; DOFETILIDE; DRUG VEHICLE; ERYTHROMYCIN; FLUCONAZOLE; FLUCYTOSINE; IMATINIB; INDINAVIR; ITRACONAZOLE; LIVER ENZYME; OMEPRAZOLE; PHENYTOIN; PREDNISOLONE; QUINIDINE; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; TERBINAFINE; TERFENADINE; TOLBUTAMIDE; UNINDEXED DRUG; VORICONAZOLE;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS TERREUS; BONE INFECTION; CANDIDA KRUSEI; CANDIDIASIS; CASE MANAGEMENT; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL TRIAL; DIARRHEA; DRUG ADMINISTRATION ROUTE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOOD DRUG INTERACTION; FUSARIUM; HEADACHE; HOSPITAL INFECTION; HUMAN; HYPERTENSION; LIVER DYSFUNCTION; LIVER FAILURE; NAUSEA; NEPHROTOXICITY; NONHUMAN; PHOTOSENSITIVITY DISORDER; REVIEW; SCEDOSPORIUM APIOSPERMUM; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; SYSTEMIC MYCOSIS; TACHYCARDIA; TERATOGENICITY; TOXIC EPIDERMAL NECROLYSIS; VISUAL DISORDER; VOMITING; YEAST;

EID: 33745462546     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: 10.2147/tcrm.2006.2.2.129     Document Type: Review

References (228)

1. 't Hek LG, Verweij PE, Weemaes CM, et al. 1998. Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease. Am J Respir Crit Care Med, 157:1694-6.
2. Ahmed J, Ditmars DM, Sheppard T, et al. 2004. Recurrence of Scedosporium apiospermum infection following renal retransplantation. Am J Transplant, 4:1720-4.
3. Alberti C, Brun-Buisson C, Burchardi H, et al. 2002. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med, 28:108-21.
4. Aliyeva SE, Ullmann AJ, Kottler UB, et al. 2004. Histological examination of an eye with endogenous Aspergillus endophthalmitis treated with oral voriconazole: a case report. Graefes Arch Clin Exp Ophthalmol, 242:887-91.
5. Ally R, Schurmann D, Kreisel W, et al. 2001. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis, 33:1447-54.
6. Alvarez-Lerma F, Nicolas-Arfelis J, Rodriguez-Borregan J, et al. 2005. Clinical use and tolerability of voriconazole in the treatment of fungal infections in critically ill patients. J Chemother, 17: 417-27.
7. Azzola A, Passweg JR, Habicht JM, et al. 2004. Use of lung resection and voriconazole for successful treatment of invasive pulmonary Aspergillus ustus infection. J Clin Microbiol, 42:4805-8.
8. Baden LR, Katz JT, Fishman JA, et al. 2003. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy. Transplantation, 76:1632-7.
9. Barchiesi F, Spreghini E, Maracci M, et al. 2004. In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata. Antimicrob Agents Chemother, 48:3317-22.
10. Bethell D, Hall G, Goodman TR, et al. 2004. Resolution of orbitocerebral aspergillosis during combination treatment with voriconazole and amphotericin plus adjunctive cytokine therapy. J Pediatr Hematol Oncol, 26:304-7.
11. Bigley VH, Duarte RF, Gosling RD, et al. 2004. Fusarium dimerum infection in a stem cell transplant recipient treated successfully with voriconazole. Bone Marrow Transplant, 34:815-17.
12. Blin N, Morineau N, Gaillard F, et al. 2004. Disseminated mucormycosis associated with invasive pulmonary aspergillosis in a patient treated for post-transplant high-grade non-Hodgkin's lymphoma. Leuk Lymphoma, 45:2161-3.
13. Bosma F, Voss A, van Hamersvelt HW, et al. 2003. Two cases of subcutaneous Scedosporium apiospermum infection treated with voriconazole. Clin Microbiol Infect, 9:750-3.
14. Boucher HW, Groll AH, Chiou CC, et al. 2004. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs, 64:1997-2020.
15. Breit SM, Hariprasad SM, Mieler WF, et al. 2005. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol, 139:135-40.
16. Burn AK, Fothergill AW, Kirkpatrick WR, et al. 2004. Comparison of antifungal susceptibilities to fluconazole and voriconazole of oral Candida glabrata isolates from head and neck radiation patients. J Clin Microbiol, 42:5846-8.
17. Caillot D, Casasnovas O, Bernard A, et al. 1997. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol, 15:139-47.
18. Cantón E, Pemán J, Gobernado, M, et al. 2005. Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods. Antimicrob Agents Chemother, 49:1593-6.
19. Capilla J, Guarro J. 2004. Correlation between in vitro susceptibility of Scedosporium apiospermum to voriconazole and in vivo outcome of scedosporiosis in guinea pigs. Antimicrob Agents Chemother, 48:4009-11.
20. Capilla J, Serena C, Pastor FJ, et al. 2003. Efficacy of voriconazole in treatment of systemic scedosporiosis in neutropenic mice. Antimicrob Agents Chemother, 47:3976-8.
21. Carrillo AJ, Guarro J. 2001. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother, 45:2151-3.
22. Castiglioni B, Sutton DA, Rinaldimg, et al. 2002. Pseudallescheria boydii (Anamorph Scedosporium apiospermum). Infection in solid organ transplant recipients in a tertiary medical center and review of the literature. Medicine (Baltimore), 81:333-48.
23. Cesaro S, Strugo L, Alaggio R, et al. 2003. Voriconazole for invasive aspergillosis in oncohematological patients: a single-center pediatric experience. Support Care Cancer, 11:722-7.
24. Chandenier J, Adou-Bryn KD, Douchet C, et al. 2004. In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia. Eur J Clin Microbiol Infect Dis, 23:506-8.
25. Chandrasekar PH, Cutright J, Manavathu E. 2000. Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model. J Antimicrob Chemother, 45:673-6.
26. Chandrasekar PH, Cutright JL, Manavathu EK. 2004. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis. Clin Microbiol Infect, 10:925-8.
27. Chandrasekar PH, Manavathu E. 2001. Voriconazole: A second-generation triazole. Drugs Today (Barc), 37:135-48.
28. Chaney S, Gopalan R, Berggren RE. 2004. Pulmonary Pseudallescheria boydii infection with cutaneous zygomycosis after near drowning. South Med J, 97:683-7.
29. Chavez M, Bernal S, Valverde A, et al. 1999. In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients. J Antimicrob Chemother, 44:697-700.
30. Chow E, Moore T, Nielsen K. 2003. Case report: Invasive aspergillosis successfully treated with voriconazole without recurrence during subsequent bone marrow transplantation. Pediatr Infect Dis J, 22:1109-10.
31. Chryssanthou E, Cuenca-Estrella M. 2002. Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J Clin Microbiol, 40:3841-4.
32. Clancy CJ, Nguyen MH. 1998. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur J Clin Microbiol Infect Dis, 17:573-5.
33. Consigny S, Dhedin N, Datry A, et al. 2003. Successsful voriconazole treatment of disseminated fusarium infection in an immunocompromised patient. Clin Infect Dis, 37:311-13.
34. Cordonnier C, Maury S, Pautas C, et al. 2004. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant, 33:943-8.
35. Corpus K, Hegeman-Dingle R, Bajjoka I. 2004. Candida kefyr, an uncommon but emerging fungal pathogen: report of two cases. Pharmacotherapy, 24:1084-88.
36. Cortez KJ, Walsh TJ, Bennett JE. 2003. Successful treatment of coccidioidal meningitis with voriconazole. Clin Infect Dis, 36:1619-22.
37. Cudillo L, Girmenia C, Santilli S, et al. 2005. Breakthrough fusariosis in a patient with acute lymphoblastic leukemia receiving voriconazole prophylaxis. Clin Infect Dis, 40:1212-13.
38. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, et al. 2004. In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates. Antimicrob Agents Chemother, 48:3107-11.
39. Cuenca-Estrella M, Rodriguez D, Almirante B, et al. 2005. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother, 55:194-9.
40. Cuenca-Estrella M, Rodriguez-Tudela JL, Mellado E, et al. 1998. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother, 42:531-3.
41. Cuenca-Estrella M, Ruíz-Díez B, Martínez-Suarez JV, et al. 1999. Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother, 43:149-51.
42. Danaher PJ, Walter EA. 2004. Successful treatment of chronic meningitis caused by Scedosporium apiospermum with oral voriconazole. Mayo Clin Proc, 79:707-8.
43. Dannaoui E, Meletiadis J, Mouton JW, et al. 2003. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother, 51:45-52.
44. de Lastours V, Lefort A, Zappa M, et al. 2003. Two cases of cerebral aspergillosis successfully treated with voriconazole. Eur J Clin Microbiol Infect Dis, 22:297-9.
45. de Pauw B. 1999. Clinical potential and experience of voriconazole [abstract]. Clin Microbiol Infect, 5(Suppl 3):7.
46. Denning D, Del Favero A, Gluckman E, et al. 1995. UK-109,496, a novel wide spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in acute invasive aspergillosis [abstract]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 17-20, San Francisco CA, USA. F80.
47. Denning DW, Ribaud P, Milpied N, et al. 2002. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis, 34:563-71.
48. Diaz-Pedroche C, Cisneros J, Lumbreras C, et al. 2005. Treatment of invasive fungal infections with voriconazole. Evaluation of experience with compassionate use of voriconazole in Spain. Rev Esp Quimioter, 18:149-58.
49. Diekema DJ, Messer SA, Hollis RJ, et al. 2003. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol, 41:3623-6.
50. Diekema DJ, Petroelje B, Messer SA, et al. 2005. Activities of available and investigational antifungal agents against Rhodotorula species. J Clin Microbiol, 43:476-8.
51. Dimopoulos G, Piagnerelli M, Berre J, et al. 2004. Post mortem examination in the intensive care unit: still useful? Intensive Care Med, 30:2080-5.
52. Donnelly JP, de Pauw BE. 2004. Voriconazole - a new therapeutic agent with an extended spectrum of antifungal activity. Clin Microbiol Infect, 10(Suppl 1):107-17.
53. Drago M, Scaltrito MM, Morace G. 2004. In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei. Eur J Clin Microbiol Infect Dis, 23:619-24.
54. Dupont B, Denning D, Lode H, et al. 1995. UK-109,496, a novel wide-spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in chronic invasive aspergillosis [abstract]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 17-20, San Francisco CA, USA. F81.
55. Durand-Joly I, Alfandari S, Benchikh Z, et al. 2003. Successful outcome of disseminated Fusarium infection with skin localization treated with voriconazole and amphotericin B-lipid complex in a patient with acute leukemia. J Clin Microbiol, 41:4898-900.
56. Eibl M, Auner HW, Zinke-Cerwenka W, et al. 2004. High-risk AML complicated by pulmonary aspergillosis: successful treatment with nonmyeloablative stem cell transplantation and long-term administration of voriconazole. Ann Hematol, 83:133-6.
57. EMEA. 2002. Vfend: European Public Assessment Report [online]. Accessed 25 August 2005. URL: http://www.emea.eu.int/humandocs/Humans/EPAR/vfend/ vfend.htm.
58. EMEA. 2005. Committee for medicinal products for human use: European Public Assessment Report (EPAR): Vfend [online]. Accessed 25 August 2005. URL: http://www.emea.eu.int/humandocs/PDFs/EPAR/vfend/ 404901en1.pdf.
59. Ernst EJ, Yodoi K, Roling EE, et al. 2002. Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, Etest, and time-kill methods. Antimicrob Agents Chemother, 46:578-81.
60. Espinel-Ingroff A. 1998. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol, 36:198-202.
61. Espinel-Ingroff A, Barchiesi F, Cuenca-Estrella M, et al. 2005. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol, 43:3884-9.
62. Espinel-Ingroff A, Boyle K, Sheehan DJ. 2001. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia, 150:101-15.
63. Espinel-Ingroff A, Fothergill A, Peter J, et al. 2002. Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J Clin Microbiol, 40:3204-8.
64. Espinel-Ingroff A, Pfaller M, Messer SA, et al. 2004. Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp. J Clin Microbiol, 42:718-21.
65. Espinel-Ingroff A, Rezusta A. 2002. E-test method for testing susceptibilities of Aspergillus spp. to the new triazoles voriconazole and posaconazole and to established antifungal agents: comparison with NCCLS broth microdilution method. J Clin Microbiol, 40:2101-7.
66. Fabry K, Verheyden F, Nelen G. 2005. Infection of a total knee prosthesis by Candida glabrata: a case report. Acta Orthop Belg, 71:119-21.
67. Favel A, Michel-Nguyen A, Datry A, et al. 2004. Susceptibility of clinical isolates of Candida lusitaniae to five systemic antifungal agents. J Antimicrob Chemother, 53:526-9.
68. FDA. 2001. Determination of regulatory review period for purposes of patent extension; Vfend [online]. Accessed 25 August 2005. URL: http://www.fda.gov/ohrms/dockets/98fr/03-9578.pdf.
69. Figueroa MS, Fortun J, Clement A, et al. 2004. Endogenous endophthalmitis caused by Scedosporium apiospermum treated with voriconazole. Retina, 24:319-20.
70. Fortun J, Martin-Davila P, Sanchez MA, et al. 2003. Voriconazole in the treatment of invasive mold infections in transplant recipients. Eur J Clin Microbiol Infect Dis, 22:408-13.
71. Friese G, Discher T, Fussle R, et al. 2001. Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease. AIDS, 15:2344-5.
72. Garau M, Pereiro M Jr, del Palacio A. 2003. In vitro susceptibilities of Malassezia species to a new triazole, albaconazole (UR-9825), and other antifungal compounds. Antimicrob Agents Chemother, 47:2342-4.
73. Garbino J, Rohner P, Kolarova L, et al. 2003. Successful treatment of pulmonary invasive aspergillosis with voriconazole in patients who failed conventional therapy. Infection, 31:241-3.
74. Garci J, Perkins A, Garau M, et al. 2003. Successful treatment with voriconazol of a Pseudallescheria boydii fungus ball in an HIV-positive patient with previous tuberculosis. Rev Iberoam Micol, 20:64-7.
75. George D, Miniter P, Andriole VT. 1996. Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother, 40:86-91.
76. German JW, Kellie SM, Pai MP, et al. 2004. Treatment of a chronic Scedosporium apiospermum vertebral osteomyelitis. Case report. Neurosurg Focus, 17:E9.
77. Ghannoum MA, Isham M, Sheehan DJ. 2005. Can we accurately assess antifungal cidality in vitro? Cidality studies of voriconazole and caspofungin against Candida species. Clin Microbiol Infect, 11 (Suppl 2):573-4.
78. Ghannoum MA, Okogbule-Wonodi I, Bhat N, et al. 1999. Antifungal activity of voriconazole (UK-109,496), fluconazole and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model. J Chemother, 11:34-9.
79. Gil-Lamaignere C, Hess R, Salvenmoser S, et al. 2005. Effect of media composition and in vitro activity of posaconazole, caspofungin and voriconazole against zygomycetes. J Antimicrob Chemother, 55:1016-19.
80. Girmenia C, Luzi G, Monaco M, et al. 1998. Use of voriconazole in treatment of Scedosporium apiospermum infection: case report. J Clin Microbiol, 36:1436-8.
81. Girmenia C, Pizzarelli G, D'Antonio D, et al. 2003. In vitro susceptibility testing of Geotrichum capitatum: comparison of the E-test, disk diffusion, and Sensititre colorimetric methods with the NCCLS M27-A2 broth microdilution reference method. Antimicrob Agents Chemother, 47:3985-8.
82. Girmenia C, Tuccinardi C, Santilli S, et al. 2000. In vitro activity of fluconazole and voriconazole against isolates of Candida albicans from patients with haematological malignancies. J Antimicrob Chemother, 46:479-83.
83. Gonzalez GM, Sutton DA, Thompson E, et al. 2001. In vitro activities of approved and investigational antifungal agents against 44 clinical isolates of basidiomycetous fungi. Antimicrob Agents Chemother, 45:633-5.
84. Gosbell IB, Toumasatos V, Yong J, et al. 2003. Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery. Mycoses, 46:233-6.
85. Granados JM, Puerto N, Carrilero MJ. 2004. Efficiency of voriconazole in fungal keratitis caused by Candida albicans. Arch Soc Esp Oftalmol, 79:565-8.
86. Green B, Lawrence C, Marr K. 2000. Voriconazole for salvage therapy of fungal infection in patients with hematological malignancies and stem cell transplantation [abstract]. Program and Abstracts of the 38th Annual Meeting of the Infection Diseases Society of America. September 7-10, New Orleans, LA, USA. 41.
87. Groll AH, Kolve H, Ehlert K, et al. 2004. Pharmacokinetic interaction between voriconazole and cyclosporin A following allogeneic bone marrow transplantation. J Antimicrob Chemother, 53:113-14.
88. Guimera-Martin-Neda F, Garcia-Bustinduy M, Noda Cabrera A, et al. 2004. Cutaneous infection by Fusarium: successful treatment with oral voriconazole. Br J Dermatol, 150:777-8.
89. Guzman-Cottrill JA, Zheng X, Chadwick EG. 2004. Fusarium solani endocarditis successfully treated with liposomal amphotericin B and voriconazole. Pediatr Infect Dis J, 23:1059-61.
90. Hegener P, Troke PF, Fatkenheuer G, et al. 1998. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS, 12:2227-8.
91. Heitmann L, Cometta A, Hurni M, et al. 1997. Right-sided pacemaker-related endocarditis due to Acremonium species. Clin Infect Dis, 25:158-60.
92. Herbrecht R. 2004. Voriconazole: therapeutic review of a new azole antifungal. Expert Rev Anti Infect Ther, 2:485-97.
93. Herbrecht R, Denning DW, Patterson TF, et al. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med, 347:408-15.
94. Hernandez PC, Llinares TF, Burgos SJ, et al. 2004. Voriconazole in fungal keratitis caused by Scedosporium apiospermum. Ann Pharmacother, 38:414-17.
95. Hilliard T, Edwards S, Buchdahl R, et al. 2005. Voriconazole therapy in children with cystic fibrosis. J Cyst Fibros, 4:215-20.
96. Howden BP, Slavin MA, Schwarer AP, et al. 2003. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis, 22:111-13.
97. Hsueh PR, Lau YJ, Chuang YC, et al. 2005. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003. Antimicrob Agents Chemother, 49:512-17.
98. Husain S, Munoz P, Forrest G, et al. 2005. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis, 40:89-99.
99. Hwang YK, Joo NH, Tee GY, et al. 2001. Clinical activity of the new triazole drug voriconazole (UK 109, 496) against disseminated hepatosplenic aspergillosis in a patient with relapsed leukemia. Haematologia (Budap), 31:73-80.
100. Imhof A, Balajee SA, Fredricks DN, et al. 2004. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis, 39:743-6.
101. Jabado N, Casanova JL, Haddad E, et al. 1998. Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease. Clin Infect Dis, 27:1437-41.
102. Jang GJ, Kim KS, Shin WS, et al. 2005. Treatment of Candida chorioretinitis with voriconazole. Korean J Ophthalmol, 19:73-6.
103. Jeu L, Piacenti FJ, Lyakhovetskiy AG, et al. 2003. Voriconazole. Clin Ther, 25:1321-81.
104. Johnson LB, Kauffman CA. 2003. Voriconazole: a new triazole antifungal agent. Clin Infect Dis, 36:630-7.
105. Kalenic S, Jandrlic M, Vegar V, et al. 2001. Hansenula anomala outbreak at a surgical intensive care unit: a search for risk factors. Eur J Epidemiol, 17:491-6.
106. Kanafani ZA, Comair Y, Kan, SS. 2004. Pseudallescheria boydii cranial osteomyelitis and subdural empyema successfully treated with voriconazole: a case report and literature review. Eur J Clin Microbiol Infect Dis, 23:836-40.
107. Kauffman CA. 2004. Zygomycosis: reemergence of an old pathogen. Clin Infect Dis, 39:588-90.
108. Khazzam M, Bansal M, Fealy S. 2005. Candida infection of the subacromial bursa. A case report. J Bone Joint Surg Am, 87:168-71.
109. Kirkpatrick WR, McAtee RK, Fothergill AW, et al. 2000. Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis. Antimicrob Agents Chemother, 44:2865-8.
110. Kirkpatrick WR, Perea S, Coco BJ, et al. 2002. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother, 46:2564-8.
111. Klasko RK. 2005. Itraconazole/Fluconazole. Drug evaluation monograph. In: Klasko RK (ed). Drugdex® system. Vol 125. Greenwood Village, CO: Thomson Micromedex. (Edition expires 09/2005).
112. Klastersky J. 2004. Antifungal therapy in patients with fever and neutropenia - more rational and less empirical? N Engl J Med, 351:1445-7.
113. Kleinpeter MA. 2004. Successful treatment of Candida infections in peritoneal dialysis patients: case reports and review of the literature. Adv Perit Dial, 20:58-61.
114. Klopfenstein KJ, Rosselet R, Termuhlen A, et al. 2003. Successful treatment of Scedosporium pneumonia with voriconazole during AML therapy and bone marrow transplantation. Med Pediatr Oncol, 41:494-5.
115. Kobayashi K, Kami M, Murashige N, et al. 2004. Breakthrough zygomycosis during voriconazole treatment for invasive aspergillosis. Haematologica, 89:ECR42.
116. Kontoyiannis DP, Lewis RE. 2004. Toward more effective antifungal therapy: the prospects of combination therapy. Br J Haematol, 126:165-75.
117. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. 2005. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis, 191:1350-60.
118. Kullberg BJ, Sobel JD, Ruhnke M, et al. 2005. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet, 366:1435-42.
119. La Nasa G, Littera R, Maccioni A, et al. 2004. Voriconazole for the treatment of disseminated nodular cutaneous aspergillosis in a patient affected by acute myeloid leukemia. Hematol J, 5:178-80.
120. Lacroix C, Feuilhade C. 2005. In vitro activities of amphotericin B, itraconazole, voriconazole and caspofungin against Scytalidium dimidiatum and Scytalidium hyalinum isolates. Mycoses, 48(Suppl 2):51.
121. Lass-Florl C, Fille M, Gunsilius E, et al. 2004. Disseminated infection with Prototheca zopfii after unrelated stem cell transplantation for leukemia. J Clin Microbiol, 42:4907-8.
122. Lassaletta A, Perez A, Diaz MA, et al. 2004. Successful treatment of invasive aspergillosis with oral voriconazole following intravenous liposomal amphotericin in a child with acute lymphoblastic leukemia. J Pediatr Hematol Oncol, 26:117-19.
123. Levin T, Suh B, Beltramo D, et al. 2004. Aspergillus mediastinitis following orthotopic heart transplantation: case report and review of the literature. Transpl Infect Dis, 6:129-31.
124. Linares MJ, Charriel G, Solis F, et al. 2004. Comparison of two microdilution methods for testing susceptibility of Candida spp. to voriconazole. J Clin Microbiol, 42:899-902.
125. Linares MJ, Charriel G, Solis F, et al. 2005. Susceptibility of filamentous fungi to voriconazole tested by two microdilution methods. J Clin Microbiol, 43:250-3.
126. Linares MJ, Solis F, Casal, M. 2005. In vitro activity of voriconazole against Prototheca wickerhamii: comparative evaluation of Sensitive and NCCLS M27-A2 methods of detection. J Clin Microbiol, 43:2520-2.
127. Lutsar I, Roffey S, Troke P. 2003. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis, 37:728-32.
128. Maesaki S, Iwakawa J, Higashiyama Y, et al. 2000. Antifungal activity of a new triazole, voriconazole (UK-109496), against clinical isolates of Aspergillus spp. J Infect Chemother, 6:101-3.
129. Manavathu EK, Cutright JL, Chandrasekar PH. 1998. Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother, 42:3018-21.
130. Marbello L, Nosari A, Carrafiello G, et al. 2003. Successful treatment with voriconazole of cerebral aspergillosis in an hematologic patient. Haematologica, 88:ECR05.
131. Marco F, Danes C, Almela M, et al. 2003. Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996-2001). Diagn Microbiol Infect Dis, 46:259-64.
132. Marco F, Pfaller MA, Messer SA, et al. 1998. Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi. Med Mycol, 36:433-6.
133. Marr KA, Boeckh M, Carter RA, et al. 2004. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis, 39:797-802.
134. Martin CA, Roberts S, Greenberg RN. 2002. Voriconazole treatment of disseminated Paecilomyces infection in a patient with acquired immunodeficiency syndrome. Clin Infect Dis, 35:e78-81.
135. Martin MV, Yates J, Hitchcock CA. 1997. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob Agents Chemother, 41:13-16.
136. Marty FM, Cosimi LA, Baden LR. 2004. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med, 350:950-2.
137. Mattei D, Mordini N, Lo NC, et al. 2003. Successful treatment of Acremonium fungemia with voriconazole. Mycoses, 46:511-14.
138. Mattei D, Mordini N, Lo NC, et al. 2002. Voriconazole in the management of invasive aspergillosis in two patients with acute myeloid leukemia undergoing stem cell transplantation. Bone Marrow Transplant, 30:967-70.
139. Mattner F, Weissbrodt H, Strueber M. 2004. Two case reports: fatal Absidia corymbifera pulmonary tract infection in the first postoperative phase of a lung transplant patient receiving voriconazole prophylaxis, and transient bronchial Absidia corymbifera colonization in a lung transplant patient. Scand J Infect Dis, 36:312-14.
140. Maxwell MJ, Messer SA, Hollis RJ, et al. 2003. Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood. J Clin Microbiol, 41:1087-90.
141. McGinnis MR, Pasarell L, Sutton DA, et al. 1998. In vitro activity of voriconazole against selected fungi. Med Mycol, 36:239-42.
142. Meletiadis J, Meis JF, Mouton JW, et al. 2002. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother, 46:62-8.
143. Minassian B, Huczko E, Washo T, et al. 2003. In vitro activity of ravuconazole against Zygomycetes, Scedosporium and Fusarium isolates. Clin Microbiol Infect, 9:1250-2.
144. Moling O, Lass-Floerl C, Verweij PE, et al. 2002. Case reports. Chronic and acute Aspergillus meningitis. Mycoses, 45:504-11.
145. Montejo M, Muñiz ML, Zárraga S, et al. 2002. Case reports. Infection due to Scedosporium apiospermum in renal transplant recipients: a report of two cases and literature review of central nervous system and cutaneous infections by Pseudallescheria boydii/Sc. apiospermum. Mycoses, 45:418-27.
146. Mouas H, Lutsar I, Dupont B, et al. 2005. Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin Infect Dis, 40:1141-7.
147. Muijsers RB, Goa KL, Scott LJ. 2002. Voriconazole in the treatment of invasive aspergillosis. Drugs, 62:2655-64.
148. Muldrew KM, Maples HD, Stowe CD, et al. 2005. Intravenous voriconazole therapy in a preterm infant. Pharmacotherapy, 25:893-8.
149. Munoz P, Marin M, Tornero P, et al. 2000. Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy. Clin Infect Dis, 31:1499-501.
150. Munoz P, Sanchez-Somolinos M, Alcala L, et al. 2005. Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital. J Antimicrob Chemother, 55:188-93.
151. Murphy M, Bernard EM, Ishimaru T, et al. 1997. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother, 41:696-8.
152. Nesky MA, McDougal EC, Peacock Jr JE, 2000. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system Pseudallescheriasis. Clin Infect Dis, 31:673-7.
153. Nulens E, Eggink C, Rijs AJ, et al. 2003. Keratitis caused by Scedosporium apiospermum successfully treated with a cornea transplant and voriconazole. J Clin Microbiol, 41:2261-4.
154. Oren I. 2005. Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin Infect Dis, 40:770-1.
155. Ostrosky-Zeichner L, Oude Lashof AM, Kullberg BJ, et al. 2003. Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis, 22:651-5.
156. Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. 2003. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother, 47:3149-54.
157. Pai MP, Jones AL. 2004. Altered susceptibility of Candida glabrata bloodstream isolates to triazoles at clinically relevant pH values: comparison of the NCCLS M27-A2, Sensititre YeastOne, and Etest methods. Antimicrob Agents Chemother, 48:4441-3.
158. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, et al. 2002. In vitro antifungal susceptibilities of Trichosporon species. Antimicrob Agents Chemother, 46:1144-6.
159. Pearson MM, Rogers PD, Cleary JD, et al. 2003. Voriconazole: a new triazole antifungal agent. Ann Pharmacother, 37:420-32.
160. Pelletier R, Loranger L, Marcotte H, et al. 2002. Voriconazole and fluconazole susceptibility of Candida isolates. J Med Microbiol, 51:479-83.
161. Pemán J, Cantón E, Gobernado M. 2005. Epidemiology and antifungal susceptibility of Candida species isolated from blood:
162. Perea S, Gonzalez G, Fothergill AW, et al. 2002. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother, 46:3039-41.
163. Perfect JR, Marr KA, Walsh TJ, et al. 2003. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis, 36:1122-31.
164. Perlroth MG, Miller J. 2004. Pseudallescheria boydii pneumonia and empyema: a rare complication of heart transplantation cured with voriconazole. J Heart Lung Transplant, 23:647-9.
165. Petit A, Tabone MD, Moissenet D, et al. 2005. Disseminated Fusarium infection in two neutropenic children. Arch Pediatr, 12:1116-19.
166. Pfaller MA, Jones RN, Doern GV, et al. 1999. International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe). Diagn Microbiol Infect Dis, 35:19-25.
167. Pfaller MA, Messer SA, Gee S, et al. 1999. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J Clin Microbiol, 37:870-2.
168. Pfaller MA, Messer SA, Hollis RJ, et al. 2002a. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother, 46:1032-7.
169. Pfaller MA, Messer SA, Hollis RJ, et al. 2002b. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother, 46:1723-1727.
170. Pfaller MA, Diekema DJ, Messer SA, et al. 2003. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J Clin Microbiol, 41:78-83.
171. Pfaller MA, Diekema DJ. 2004. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol, 42:4419-31.
172. Pfaller MA, Espinel-Ingroff A, Jones RN. 2004. Clinical evaluation of the Sensititre YeastOne calorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole. J Clin Microbiol, 42:4577-80.
173. Pfaller MA, Messer SA, Boyken L, et al. 2004. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis, 48:201-5.
174. Pfaller MA, Boyken L, Messer SA, et al. 2005. Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program. J Clin Microbiol, 43:5208-13.
175. Pfaller MA, Messer SA, Boyken L, et al. 2005. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol, 43:2163-7.
176. Polizzi A, Siniscalchi C, Mastromarino A, et al. 2004. Effect of voriconazole on a corneal abscess caused by Fusarium. Acta Ophthalmol Scand, 82:762-4.
177. Poza G, Montoya J, Redondo C, et al. 2000. Meningitis caused by Pseudallescheria boydii treated with voriconazole. Clin Infect Dis, 30:981-2.
178. Prabhu RM, Bonnell M, Currier BL, et al. 2004. Successful treatment of disseminated nonmeningeal coccidioidomycosis with voriconazole. Clin Infect Dis, 39:e74-7.
179. Purkins L, Wood N, Kleinermans D, et al. 2003. Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br J Clin Pharmacol, 56(Suppl 1):24-9.
180. Puzniak L, Teutsch S, Powderly W, et al. 2004. Has the epidemiology of nosocomial candidemia changed? Infect Control Hosp Epidemiol, 25:628-33.
181. Quindós G, Carrillo-Muñoz AJ, Arévalo MP, et al. 2000. In vitro susceptibility of Candida dubliniensis to current and new antifungal agents. Chemotherapy, 46:395-401.
182. Radford SA, Johnson EM, Warnock DW. 1997. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob Agents Chemother, 41:841-3.
183. Reis A, Sundmacher R, Tintelnot K, et al. 2000. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole. Br J Ophthalmol, 84:932-3.
184. Reis LJ, Barton TD, Pochettino A, et al. 2005. Successful treatment of Aspergillus prosthetic valve endocarditis with oral voriconazole. Clin Infect Dis, 41:752-3.
185. Rodriguez CA, Lujan-Zilbermann J, Woodard P, et al. 2003. Successful treatment of disseminated fusariosis. Bone Marrow Transplant, 31:411-12.
186. Rodriguez-Tudela JL, Diaz-Guerra TM, Mellado E, et al. 2005. Susceptibility patterns and molecular identification of Trichosporon species. Antimicrob Agents Chemother, 49:4026-34.
187. Rosen-Wolff A, Koch A, Friedrich W, et al. 2004. Successful elimination of an invasive Aspergillus nidulans lung infection by voriconazole after failure of a combination of caspofungin and liposomal amphotericin B in a boy with chronic granulomatous disease. Pediatr Infect Dis J, 23:584-6.
188. Rubio MC, Gil J, Ramírez de Ocariz I, et al. 2003. In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp. Rev Esp Quimioter, 16:227-32.
189. Rubio MC, Ramírez de Ocariz IR, Gil J, et al. 2005. Potential fungicidal effect of voriconazole against Candida spp. Int J Antimicrob Agents, 25:264-7.
190. Sabo JA, Abdel-Rahman SM. 2000. Voriconazole: a new triazole antifungal. Ann Pharmacother, 34:1032-43.
191. Sadaba B, Campanero MA, Quetglas EG, et al. 2004. Clinical relevance of sirolimus drug interactions in transplant patients. Transplant Proc, 36:3226-8.
192. Sambatakou H, Guiver M, Denning D. 2003. Pulmonary aspergillosis in a patient with chronic granulomatous disease: confirmation by polymerase chain reaction and serological tests, and successful treatment with voriconazole. Eur J Clin Microbiol Infect Dis, 22:681-5.
193. Schaenman JM, Digiulio DB, Mirels LF, et al. 2005. Scedosporium apiospermum soft tissue infection successfully treated with voriconazole: potential pitfalls in the transition from intravenous to oral therapy. J Clin Microbiol, 43:973-7.
194. Schlamm H, Corey L, Brown J, et al. 2000. Voriconazole for salvage treatment of invasive aspergillosis [abstract]. Clin Infect Dis, 31:265.
195. Schlamm H, Supparatpnyo K. 2003. Voriconazole as therapy for systemic infections caused by Penicillium marneffei in patients with HIV infection [abstract]. 43rd Interscience Conference on Antimicrobial Agents Chemotherapy, September 14-17, Chicago, IL, USA. M-963.
196. Schwartz S, Ruhnke M, Ribaud P, et al. 2005. Improved outcome in central nervous system aspergillosis with voriconazole treatment. Blood, 106:2641-5.
197. Serrano MC, Ramirez M, Morilla D, et al. 2004. A comparative study of the disc diffusion method with the broth microdilution and Etest methods for voriconazole susceptibility testing of Aspergillus spp. J Antimicrob Chemother, 53:739-42.
198. Serrano MC, Valverde-Conde A, Chavez MM, et al. 2003. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against Aspergillus spp. Diagn Microbiol Infect Dis, 45:131-5.
199. Serrano-Martino MC, Chavez-Caballero M, Valverde-Conde A, et al. 2003. In vitro activity of voriconazole and three other antifungal agents against dermatophytes. Enferm Infecc Microbiol Clin, 21:484-7.
200. Shouldice E, Fernandez C, McCully B, et al. 2003. Voriconazole treatment of presumptive disseminated Aspergillus infection in a child with acute leukemia. J Pediatr Hematol Oncol, 25:732-4.
201. Siwek GT, Dodgson KJ, Magalhaes-Silverman M, et al. 2004. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis, 39:584-7.
202. Steinbach WJ. 2005. Antifungal agents in children. Pediatr Clin North Am, 52:895-915.
203. Steinbach WJ, Benjamin DK Jr, Kontoyiannis DP, et al. 2004. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis, 39:192-8.
204. Steinbach WJ, Schell WA, Miller JL, et al. 2003. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide. J Clin Microbiol, 41:3981-5.
205. Stern JB, Girard P, Caliandro R. 2004. Pleural diffusion of voriconazole in a patient with Aspergillus fumigatus empyema thoracis. Antimicrob Agents Chemother, 48:1065.
206. Stratov I, Korman TM, Johnson PD. 2003. Management of Aspergillus osteomyelitis: report of failure of liposomal amphotericin B and response to voriconazole in an immunocompetent host and literature review. Eur J Clin Microbiol Infect Dis, 22:277-83.
207. Studahl M, Backteman T, Stalhammar F, et al. 2003. Bone and joint infection after traumatic implantation of Scedosporium prolificans treated with voriconazole and surgery. Acta Paediatr, 92:980-2.
208. Sugar AM, Liu XP. 2001. Efficacy of voriconazole in treatment of murine pulmonary blastomycosis. Antimicrob Agents Chemother, 45:601-4.
209. Swift AC, Denning DW. 1998. Skull base osteitis following fungal sinusitis. J Laryngol Otol, 112:92-7.
210. Swinne D, Watelle M, Nolard N. 2005. In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non-Candida albicans yeast isolates. Rev Iberoam Micol, 22:24-8.
211. Swinne D, Watelle M, van der Flaes M, et al. 2004. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study). Mycoses, 47:177-83.
212. Takakura S, Fujihara N, Saito T, et al. 2004. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J Antimicrob Chemother, 53:283-9.
213. Tattevin P, Bruneel F, Lellouche F, et al. 2004. Successful treatment of brain aspergillosis with voriconazole. Clin Microbiol Infect, 10:928-31.
214. Tortorano AM, Pemán J, Bernhardt H, et al. 2004. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis, 23:317-22.
215. Tortorano AM, Rigoni AL, Biraghi E, et al. 2003. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: antifungal susceptibility patterns of 261 non-albicans Candida isolates from blood. J Antimicrob Chemother, 52:679-82.
216. Trinh JV, Steinbach WJ, Schell WA, et al. 2003. Cerebral phaeohyphomycosis in an immunodeficient child treated medically with combination antifungal therapy. Med Mycol, 41:339-45.
217. Troke P, Schwartz S, Ruhnke M, et al. 2003. Voriconazole therapy in 86 patients with CNS aspergillosis: a retrospective analysis [abstract]. 43th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 14-17, Chicago, IL, USA. M-1755.
218. Uzun O, Arikan S, Kocagoz S, et al. 2000. Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish University Hospital and effect of time of reading. Diagn Microbiol Infect Dis, 38:101-7.
219. van Duin D, Cleare W, Zaragoza O, et al. 2004. Effects of voriconazole on Cryptococcus neoformans. Antimicrob Agents Chemother, 48:2014-20.
220. Varma D, Thaker HR, Moss PJ, et al. 2005. Use of voriconazole in candida retinitis. Eye, 19:485-7.
221. Vazquez JA, Lynch M, Boikov D, et al. 1997. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and - resistant Candida species. Antimicrob Agents Chemother, 41:1612-14.
222. Venkataramanan R, Zang S, Gayowski T, et al. 2002. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob Agents Chemother, 46:3091-3.
223. Verweij PE, van den Bergh MF, Rath PM, et al. 1999. Invasive aspergillosis caused by Aspergillus ustus: case report and review. J Clin Microbiol, 37:1606-9.
224. Vigouroux S, Morin O, Moreau P, et al. 2005. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis, 40:e35-7.
225. Vincent AL, Cabrero JE, Greene JN, et al. 2003. Successful voriconazole therapy of disseminated Fusarium solani in the brain of a neutropenic cancer patient. Cancer Control, 10:414-19.
226. Walsh TJ, Lutsar I, Driscoll T, et al. 2002. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J, 21:240-8.
227. Walsh TJ, Pappas P, Winston DJ, et al. 2002. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med, 346:225-34.
228. Yang YL, Cheng HH, Lo HJ. 2004. In vitro activity of voriconazole against Candida species isolated in Taiwan. Int J Antimicrob Agents, 24:294-6.